{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:50:17Z","timestamp":1790013017385,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.eururo.2007.10.006","type":"journal-article","created":{"date-parts":[[2007,10,25]],"date-time":"2007-10-25T06:07:24Z","timestamp":1193292444000},"page":"992-1002","source":"Crossref","is-referenced-by-count":224,"title":["Prognostic Factors in Patients with Non\u2013Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin: Multivariate Analysis of Data from Four Randomized CUETO Trials"],"prefix":"10.1016","volume":"53","author":[{"given":"Jesus","family":"Fernandez-Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Solsona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Unda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Martinez-Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelino","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Madero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ojea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pertusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Rodriguez-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Emilio","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Isorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Rabadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Astobieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Munta\u00f1ola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Blas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Martinez-Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2007.10.006_bib1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","article-title":"Primary superficial bladder cancer risk groups according to progression, mortality and recurrence","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1570-9124(03)00016-3","article-title":"BCG immunotherapy for superficial bladder cancer: an overview of the past, the present and the future","volume":"1","author":"van der Meijden","year":"2003","journal-title":"EAU Update Series"},{"key":"10.1016\/j.eururo.2007.10.006_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib4","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy exist? Analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2007.10.006_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non\u2013muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.eururo.2007.02.064","volume":"52","author":"Evans","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2007.10.006_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1442-2042.1997.tb00160.x","article-title":"Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Gu\u00e9rin: a long-term follow-up","volume":"4","author":"Shinka","year":"1997","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"European Organisation Research and Treatment of Cancer Genitourinary. The ablative effect of quarter dose bacillus Gu\u00e9rin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib16","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)64361-3","article-title":"Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Gu\u00e9rin (modified Danish 1331 strain) for superficial bladder cancer","volume":"168","author":"Kumar","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1445-2197.2004.02941.x","article-title":"Low dose adjuvant therapy for superficial bladder cancer literature review","volume":"74","author":"Cheng","year":"2004","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.eururo.2007.10.006_bib18","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib19","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.eururo.2007.05.010","article-title":"What is the optimal BCG dose in non\u2013muscle-invasive bladder cancer?","volume":"52","author":"Witjes","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib20","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Gu\u00e9rin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib21","unstructured":"Solsona E, Gonzalez M, Fernandez JM, Unda M, Bernuy C, Pertusa C, members of CUETO Group Random trial comparing intravesical chemo-induction with MMC to immunotherapy with BCG versus intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Preliminary results of the CUETO Trial no. 93009. Abstract. XIXth Congress of the European Association of Urology, Vienna, 2004."},{"key":"10.1016\/j.eururo.2007.10.006_bib22","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0022-5347(01)65458-2","article-title":"Low dose Pasteur bacillus Calmette-Gu\u00e9rin regime in stage T1, grade 3 bladder cancer therapy","volume":"156","author":"Hurle","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000019664","article-title":"Low dose BCG instillations in the treatment of stage T1 grade 3","volume":"34","author":"Lebret","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Gu\u00e9rin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","article-title":"Bacillus Calmette-Gu\u00e9rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group","volume":"75","author":"Akaza","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2007.10.006_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Gu\u00e9rin in patients with superficial bladder carcinoma","volume":"56","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose Bacillus Calmette-Gu\u00e9rin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Gu\u00e9rin: progression-free and disease specific survival with 10-year minimum follow-up","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-5347(01)61770-1","article-title":"Correlation and prognostic significance of p53, p21WAF1\/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Gu\u00e9rin intravesical therapy","volume":"161","author":"Zlotta","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","article-title":"Superficial bladder cancer treated with Bacillus Calmette-Gu\u00e9rin: a multivariate analysis of factors affecting tumor progression","volume":"141","author":"Herr","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0022-5347(17)37317-2","article-title":"Management of local Bacillus Calmette-Gu\u00e9rin failures in superficial bladder cancer","volume":"147","author":"Klein","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib33","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0022-5347(01)64825-0","article-title":"Long-term efficacy of intravesical bacillus Calmette-Gu\u00e9rin for carcinoma in situ: relationship of progression to histologic response and p53 nuclear accumulation","volume":"157","author":"Ovesen","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacillus Calmette\u2013Gu\u00e9rin in stage T1 grade 3 bladder cancer therapy: a 7-years follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.10.006_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Gu\u00e9rin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.10.006_bib36","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Gu\u00e9rin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2003.11.027","article-title":"T1G3 Bladder cancer: conservative management or cystectomy?","volume":"45","author":"Gattegno","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.10.006_bib41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"issue":"Suppl 6A","key":"10.1016\/j.eururo.2007.10.006_bib42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage t1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807012560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807012560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T20:20:52Z","timestamp":1556914852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283807012560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0302283807012560"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2007.10.006","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}